Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Hal Mintz, Sabby Management Report 7.43% Stake in Oxygen Biotherapeutics, Inc. (OXBT)

Hal Mintz‘ Sabby Management has reported a new stake in the biotechnology company Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT), a new filing with the SEC shows. Sabby currently owns over 1.96 million shares of the company, equal to 7.43% of the outstanding stock. The value of the passive position amounts to around $11.61 million, at the current price of the company’s stock.

Oxygen Biotherapeutics

Interestingly, Sabby Management purchased the shares of Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT), after disclosing in its latest 13F filing, dumping the holding, which previously contained some 36,700 shares. Out of the funds that we track, Ellington, led by Mike Vranos, is the only one that disclosed holding Oxygen Biotherapeutics in its equity portfolio as at the end of last year. Ellington’s stake amasses 34,200 shares, with a reported value of $154,000.

Sabby’s latest acquisition falls in line with the recently announced public offering launched by Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT). The company intends to sell around $52 million worth of stock, for a price of $5.60 per share, Oxygen Biotherapeutics said in a statement. The proceeds will be used for company’s clinical trials as well as for obtaining regulatory approvals for two of its drugs: Levosimendan and Oxycyte. In addition the company will also spend the cash it receives from the proceeds to support the manufacturing of the aforementioned drugs and for development of other product candidates, the statement added.

Moreover, at the beginning of March, Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT) announced that its Oxycyte drug has been reviewed by U.S. FDA agency, which decided to lift the clinical hold of the drug, which means a green light for the clinical development of the product in the U.S, another press release said.

On the back of positive news related to the development of the company, the stock of Oxygen Biotherapeutics has been gaining ground since the beginning of the year, and is already 30% year-to-date.

Recently, Sabby Management disclosed adding other two Healthcare stocks to its equity portfolio. The fund disclosed ownership of 437,500 shares of Recro Pharma Inc (NASDAQ:REPH) and 1.7 million shares of Bioline RX Ltd (NASDAQ:BLRX), both stakes amassing around 5% of the companies’.

Disclosure: none

Recommended Reading:

RA Capital Discloses New Passive Stake in Repros Therapeutics Inc (RPRX)

Steven Cohen Ups His Bets on NQ Mobile Inc (ADR) (NQ)

Himanshu H. Shah Ups Stake in Corinthian Colleges Inc (COCO); Sends Letter to the Board

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!